Our top pick for
IVERIC bio, Inc is a biotechnology business based in the US. IVERIC bio shares (ISEE) are listed on the NASDAQ and all prices are listed in US Dollars. IVERIC bio employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$3.51 - $7.98|
|50-day moving average||$6.20|
|200-day moving average||$6.23|
|Wall St. target price||$13.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-62,784,000|
|Return on assets TTM||-31.97%|
|Return on equity TTM||-54.76%|
|Market capitalisation||$615.9 million|
TTM: trailing 12 months
There are currently 5.3 million IVERIC bio shares held short by investors – that's known as IVERIC bio's "short interest". This figure is 0.4% up from 5.3 million last month.
There are a few different ways that this level of interest in shorting IVERIC bio shares can be evaluated.
IVERIC bio's "short interest ratio" (SIR) is the quantity of IVERIC bio shares currently shorted divided by the average quantity of IVERIC bio shares traded daily (recently around 476235.93189964). IVERIC bio's SIR currently stands at 11.16. In other words for every 100,000 IVERIC bio shares traded daily on the market, roughly 11160 shares are currently held short.
However IVERIC bio's short interest can also be evaluated against the total number of IVERIC bio shares, or, against the total number of tradable IVERIC bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IVERIC bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 IVERIC bio shares in existence, roughly 60 shares are currently held short) or 0.0593% of the tradable shares (for every 100,000 tradable IVERIC bio shares, roughly 59 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against IVERIC bio.
Find out more about how you can short IVERIC bio stock.
We're not expecting IVERIC bio to pay a dividend over the next 12 months.
Over the last 12 months, IVERIC bio's shares have ranged in value from as little as $3.51 up to $7.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IVERIC bio's is 1.6669. This would suggest that IVERIC bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IVERIC bio, Inc. , a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.